Repare Therapeutics IncNASDAQ:RPTX
- LAST PRICE3.3200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.1300/ 1
- Ask / Lots3.6400/ 1
- Open / Previous Close--- / 3.3200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPTX |
|---|---|---|
| 09:32 ET | 6601 | 3.14 |
| 09:35 ET | 300 | 3.08 |
| 09:39 ET | 2000 | 3.0832 |
| 09:42 ET | 400 | 3.2 |
| 09:44 ET | 100 | 3.09 |
| 09:55 ET | 100 | 3.17 |
| 09:57 ET | 1300 | 3.167 |
| 10:00 ET | 100 | 3.18 |
| 10:02 ET | 1820 | 3.15 |
| 10:04 ET | 100 | 3.165 |
| 10:06 ET | 2301 | 3.1712 |
| 10:08 ET | 972 | 3.18 |
| 10:09 ET | 10103 | 3.2101 |
| 10:11 ET | 836 | 3.215 |
| 10:13 ET | 603 | 3.2 |
| 10:20 ET | 500 | 3.16 |
| 10:22 ET | 4502 | 3.2 |
| 10:26 ET | 2083 | 3.205 |
| 10:29 ET | 100 | 3.18 |
| 10:31 ET | 100 | 3.16 |
| 10:33 ET | 1250 | 3.14 |
| 10:44 ET | 900 | 3.125 |
| 10:49 ET | 100 | 3.13 |
| 10:51 ET | 100 | 3.17 |
| 11:09 ET | 100 | 3.18 |
| 11:14 ET | 200 | 3.14 |
| 11:16 ET | 100 | 3.18 |
| 11:18 ET | 475 | 3.1604 |
| 11:23 ET | 1095 | 3.18 |
| 11:25 ET | 1500 | 3.1799 |
| 11:27 ET | 6290 | 3.18 |
| 11:32 ET | 100 | 3.2 |
| 11:34 ET | 2500 | 3.18 |
| 11:36 ET | 200 | 3.17 |
| 11:38 ET | 200 | 3.17 |
| 11:48 ET | 100 | 3.14 |
| 11:54 ET | 208 | 3.18 |
| 11:56 ET | 960 | 3.185 |
| 11:59 ET | 100 | 3.2 |
| 12:01 ET | 300 | 3.17 |
| 12:06 ET | 475 | 3.1749 |
| 12:08 ET | 100 | 3.2 |
| 12:17 ET | 100 | 3.18 |
| 12:19 ET | 633 | 3.1929 |
| 12:24 ET | 400 | 3.185 |
| 12:28 ET | 424 | 3.2 |
| 12:37 ET | 100 | 3.19 |
| 12:39 ET | 704 | 3.22 |
| 12:42 ET | 299 | 3.23 |
| 12:44 ET | 100 | 3.21 |
| 12:48 ET | 300 | 3.23 |
| 12:50 ET | 265 | 3.24 |
| 12:51 ET | 300 | 3.24 |
| 12:53 ET | 400 | 3.225 |
| 12:57 ET | 100 | 3.24 |
| 01:00 ET | 100 | 3.24 |
| 01:02 ET | 100 | 3.24 |
| 01:04 ET | 225 | 3.225 |
| 01:06 ET | 500 | 3.225 |
| 01:09 ET | 100 | 3.25 |
| 01:11 ET | 600 | 3.22 |
| 01:13 ET | 500 | 3.23 |
| 01:18 ET | 1730 | 3.265 |
| 01:20 ET | 100 | 3.26 |
| 01:22 ET | 1599 | 3.28 |
| 01:24 ET | 494 | 3.28 |
| 01:27 ET | 200 | 3.28 |
| 01:29 ET | 300 | 3.29 |
| 01:31 ET | 655 | 3.28 |
| 01:33 ET | 300 | 3.265 |
| 01:38 ET | 400 | 3.265 |
| 01:44 ET | 100 | 3.29 |
| 01:47 ET | 400 | 3.25 |
| 01:51 ET | 600 | 3.25 |
| 02:02 ET | 1000 | 3.25 |
| 02:03 ET | 100 | 3.25 |
| 02:05 ET | 100 | 3.28 |
| 02:07 ET | 858 | 3.245 |
| 02:12 ET | 2920 | 3.25 |
| 02:16 ET | 609 | 3.25 |
| 02:18 ET | 200 | 3.255 |
| 02:20 ET | 300 | 3.245 |
| 02:21 ET | 300 | 3.245 |
| 02:32 ET | 2033 | 3.23 |
| 02:34 ET | 100 | 3.23 |
| 02:36 ET | 200 | 3.2571 |
| 02:38 ET | 300 | 3.23 |
| 02:39 ET | 1356 | 3.26 |
| 02:48 ET | 700 | 3.255 |
| 02:56 ET | 200 | 3.25 |
| 02:57 ET | 280 | 3.27 |
| 02:59 ET | 800 | 3.275 |
| 03:06 ET | 1100 | 3.285 |
| 03:10 ET | 400 | 3.285 |
| 03:12 ET | 800 | 3.28 |
| 03:15 ET | 800 | 3.27 |
| 03:17 ET | 100 | 3.27 |
| 03:19 ET | 100 | 3.26 |
| 03:21 ET | 300 | 3.28 |
| 03:24 ET | 132 | 3.3 |
| 03:26 ET | 300 | 3.29 |
| 03:28 ET | 300 | 3.3 |
| 03:30 ET | 200 | 3.31 |
| 03:32 ET | 383 | 3.31 |
| 03:33 ET | 400 | 3.32 |
| 03:35 ET | 900 | 3.335 |
| 03:37 ET | 200 | 3.34 |
| 03:42 ET | 1819 | 3.32 |
| 03:46 ET | 800 | 3.3 |
| 03:50 ET | 200 | 3.305 |
| 03:51 ET | 200 | 3.305 |
| 03:53 ET | 485 | 3.32 |
| 03:55 ET | 1212 | 3.34 |
| 03:57 ET | 1100 | 3.34 |
| 04:00 ET | 8943 | 3.32 |
Nov 12, 2024
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib, from 7:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 8, 2024
DJ Repare Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 11:46AM ET on Friday Nov 08, 2024 by Dow Jones
11:46AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
*DJ Repare Therapeutics 3Q Loss/Shr 81c >RPTX, from 7:05AM ET on Thursday Nov 07, 2024 by Dow Jones
7:05AM ET on Thursday Nov 07, 2024 by Dow JonesRepare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results, from 7:05AM ET on Thursday Nov 07, 2024 by Dow Jones
7:05AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Repare Therapeutics Inc | 133.9M | -1.7x | --- |
Innate Pharma SA | 123.0M | -3.4x | --- |
Champions Oncology Inc | 58.6M | -17.0x | --- |
Cidara Therapeutics Inc | 142.3M | -0.8x | --- |
Precision BioSciences Inc | 54.5M | 9.3x | --- |
Adaptimmune Therapeutics PLC | 174.0M | -3.4x | --- |
Company Information
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Contact Information
- Headquarters
- 7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Thomas Civik
- President, Chief Executive Officer, Director
- Lloyd Segal
- Chief Financial Officer, Executive Vice President
- Steve Forte
- Executive Vice President, Chief Scientific Officer
- Michael Zinda
- Executive Vice President, Chief Medical Officer
- Maria Koehler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $133.9M |
|---|---|
Revenue (TTM) | $66.5M |
Shares Outstanding | 42.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-2.00 |
Book Value | $5.03 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -140.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
